Bispecific antibody therapies are a groundbreaking advancement in cancer treatment, offering new options for patients when traditional therapies may not be enough. These innovative treatments offer new hope, especially, for patients with cancers that may be resistant to traditional treatments. Bispecific therapies work by harnessing the body’s immune system to effectively identify, target, and eliminate cancer cells.

What are Bispecific Antibodies?

Unlike conventional treatments, bispecific antibodies used in cancer therapy are special proteins engineered to simultaneously bind to both cancer cells and T-cells, a type of immune cell responsible for attacking harmful invaders. By forming this connection, they help the immune system recognize and destroy cancer cells more effectively. Think of them like a bridge linking two distant islands.

How Bispecific Antibodies work?

How are bispecific antibodies being used in cancer care at AON?

At American Oncology Network (AON), we are committed to staying at the forefront of cancer care by incorporating innovative treatments like bispecific antibodies. Our expert team of oncology professionals uses these therapies to enhance patient outcomes. By connecting immune cells to cancer cells, bispecific antibodies help us offer cutting-edge treatment options tailored to each patient’s needs.

Additionally, AON actively participates in clinical trials and collaborates with leading researchers to advance the use of bispecific antibodies in cancer treatment. Our goal is to continue exploring the potential of these therapies to improve quality of life and treatment effectiveness for our patients.

As of March 2025, AON has provided bispecific antibody therapy to patients diagnosed with the following conditions:

• Acute Lymphoblastic Leukemia
• Uveal Melanoma
• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma
• Multiple Myeloma
• Extensive-Stage Small Cell Lung Cancer

Treatment Considerations and Safety

When using bispecific antibodies, it’s important to consider several factors to optimize treatment outcomes and minimize risks. These factors include patient eligibility, potential side effects, and the need for monitoring during therapy.

• Patient Eligibility – Bispecific antibody therapies are typically prescribed for patients with specific types of cancers, such as certain leukemias and lymphomas. They are most effective when used in combination with other treatments like chemotherapy or immunotherapy. However, patient health and previous treatments must be carefully assessed before starting therapy.
• Side Effects – Like any cancer treatment, bispecific antibodies can cause side effects. The most common include cytokine release syndrome (CRS), neurotoxicity, and infection risks due to the immune system’s response. CRS, in particular, requires immediate medical attention and may be life threatening. Bispecific therapies are initially administered using a step-up dosing approach, which gradually increases dosage to help reduce the risk of severe side effects.
• Monitoring and Supportive Care – Regular monitoring is essential during bispecific antibody treatment. To ensure patient safety, initial doses are typically given in a hospital setting, where patients are closely observed for signs of adverse reactions, especially in the initial treatment phases.

Listen to AON’s Podcast Episodes About BiTE

• Bispecific T-Cell Engaging Therapies in Community Oncology RxConnect Podcast S1:E5 | Listen
• Overcoming Challenges to Initiate Bispecifics RxConnect Podcast S2:E1 | Listen
• Overcoming Challenges in Initiating Bispecific Therapy RxConnect Podcast S2:E4 | Listen
• Learning More About BiSpecific Therapy and Implementation RxConnect Podcast S2:E6 | Listen

Articles About Bispecific Antibodies Use in Cancer Care

Bispecific Antibodies: A New Frontier in Cancer Immunotherapy
American Cancer Society (2023) | Read more

Pharmacists at the Forefront: The Evolving Landscape of Bispecific Antibodies in Cancer Care
Pharmacy Times (2022) | Read more

Bispecific Antibodies: A 50-Year-Old Idea Catches Fire
National Cancer Institute (2021) | Read more